Involvement made possible by RUNDIPG
Dr. Nick Vitanza is a physician-scientist who completed fellowships in oncology (New York University) and neuro-oncology (Stanford University). At Seattle Children’s, he serves as the DIPG Research Lead and directs a lab focused on the biologic and immunologic targeting of fatal pediatric central nervous system (CNS) tumors, such as diffuse intrinsic pontine glioma (DIPG) and diffuse midline glioma (DMG). He also serves as the CNS CAR T cell Lead and has directed multiple repeatedly intracranially dosed CNS CAR T cell trials (including BrainChild-01 targeting HER2 published in Nature Medicine, BrainChild-03 targeting B7-H3 published in Cancer Discovery, and BrainChild-04 using quad-targeting CAR T cells). Ultimately, his focus is rapidly advancing novel therapeutics for children with fatal CNS tumors.
